Bern, Get Ready (BEready) Cohort Study for Pandemic Preparedness
NCT06739499 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 2157
Last updated 2026-02-05
Summary
The BEready project aims to find out how people in the Canton of Bern can be helped to be more prepared for the next pandemic. BEready wants to understand how infections spread among people as well as between people and animals. BEready wants to find out how social and environmental factors can influence the transmission or catching of infectious diseases. BEready wants to better understand how households and their pets in the Canton of Bern were and continue to be affected by the coronavirus disease 2019 (COVID-19).
Conditions
- Pandemic, COVID-19
- Infections
- Zoonoses
- Epidemic Disease
- Respiratory Tract Infections
Sponsors & Collaborators
-
Stiftung Vinetum
collaborator UNKNOWN -
University of Bern
lead OTHER
Principal Investigators
-
Nicola Low, Prof. Dr. med. · University of Bern
Eligibility
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2024-04-29
- Primary Completion
- 2100-12-31
- Completion
- 2100-12-31
Countries
- Switzerland
Study Locations
Related Clinical Trials
-
Bifeprunox Extension to Extension Study in Patients With Schizophrenia
NCT00861497 · Status: TERMINATED · Phase: PHASE3
- Schizophrenia
-
Twice Daily Titration Study of Bifeprunox in Subjects With Schizophrenia
NCT00139906 · Status: COMPLETED · Phase: PHASE2
- Schizophrenia
- Schizoaffective Disorder
-
Progressively Decreasing Titration Schedules of Bifeprunox in Subjects With Schizophrenia or Bipolar Disorder
NCT00139919 · Status: COMPLETED · Phase: PHASE2
- Schizophrenia
- Schizoaffective Disorder
- Bipolar Disorder
-
Study Evaluating the Tolerability of Bifeprunox in Healthy Subjects
NCT00581451 · Status: COMPLETED · Phase: PHASE1
- Healthy
-
Study Evaluating Bifeprunox in Patients With Schizophrenia.
NCT00366327 · Status: TERMINATED · Phase: PHASE3
- Schizophrenia
More Related Trials
-
Study Comparing Bifeprunox to Risperidone in Treatment of Outpatients With Schizophrenia With Weight as Primary Endpoint
NCT00366704 ·Status: TERMINATED ·Phase: PHASE3
-
Open Label Extension Study of Bifeprunox
NCT00366171 ·Status: COMPLETED ·Phase: PHASE3
-
Bifeprunox in the Treatment of Schizophrenia
NCT00193687 ·Status: COMPLETED ·Phase: PHASE3
-
To Evaluate the Impact of Treatment Interruption on Re-initiation of Bifeprunox
NCT00141479 ·Status: COMPLETED ·Phase: PHASE2
-
Study Comparing the Affect of Bifeprunox Vs Olanzapine on Weight During the Treatment of Outpatients With Schizophrenia.
NCT00380224 ·Status: COMPLETED ·Phase: PHASE3
-
Compare the Effects of Bifeprunox and Quetiapine on Weight Changes in Stable Schizophrenic Patients
NCT00396214 ·Status: TERMINATED ·Phase: PHASE3
-
Bifeprunox in the Treatment of Schizophrenia
NCT00193713 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment of Elderly Subjects With Psychosis and Behavioral Disturbances Associated With Dementia of the Alzheimer's Type
NCT00160147 ·Status: TERMINATED ·Phase: PHASE3
-
A Study of RO4917838 (Bitopertin) in Patients With Persistent, Predominant Negative Symptoms of Schizophrenia (WN25309)
NCT01192906 ·Status: COMPLETED ·Phase: PHASE3
-
PK Effects of Bifeprunox & Valproate in Bipolar I
NCT00141505 ·Status: COMPLETED ·Phase: PHASE2
-
Study Evaluating Bifeprunox in Bipolar Depression
NCT00245973 ·Status: COMPLETED ·Phase: PHASE3
-
Bioequivalence Study in Healthy Men and Women to Compare Two Pharmaceutical Formulations of Flupentixol/Melitracen (Deanxit®)
NCT02179931 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate Efficacy and Safety of Bitopertin in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia
NCT01192880 ·Status: COMPLETED ·Phase: PHASE3
-
Patient-reported Outcomes in the Treatment of Schizophrenia
NCT00230828 ·Status: COMPLETED ·Phase: PHASE3
-
Study Evaluating Bifeprunox in Bipolar Depression
NCT00134459 ·Status: COMPLETED ·Phase: PHASE3
-
Geodon in Weight Loss Study for Bipolar Disorders
NCT00472641 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25306)
NCT01235585 ·Status: COMPLETED ·Phase: PHASE3
-
Bioequivalence Study to Compare Two Formulations of Deanxit®
NCT03472651 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25305)
NCT01235559 ·Status: COMPLETED ·Phase: PHASE3
-
Switch Study of Existing Atypical Antipsychotics to Bifeprunox
NCT00347425 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy of Bifeprunox in Patients With Schizophrenia
NCT00704509 ·Status: TERMINATED ·Phase: PHASE3
-
Efficacy of Bifeprunox in Patients With Schizophrenia
NCT00658645 ·Status: TERMINATED ·Phase: PHASE3
-
Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia
NCT01668797 ·Status: COMPLETED ·Phase: PHASE3
-
Bio-equivalence Study Between SAPHRIS and Asenapine
NCT01948024 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions
NCT06494397 ·Status: COMPLETED ·Phase: PHASE1